Table 4 Central composite plan of anti-viral drugs
S.No. | Trials | Organic phase | pH | Flow rate | Responses (Sof + Vel + Led + Dac) | |||
|---|---|---|---|---|---|---|---|---|
X1 | X2 | X3 | TP1 | TP2 | TP3 | TP4 | ||
1 | I | 30 | 4.0 | 0.6 | 17,398.754 | 921 | 955 | 934 |
2 | X1 | 70 | 4.0 | 0.6 | 2845.40 | 7132.22 | 4852.92 | 1506.5 |
3 | X2 | 30 | 6.0 | 0.6 | 19,215.652 | 932 | 965 | 956 |
4 | X1X2 | 70 | 6.0 | 0.6 | 8357.634 | 8403.91 | 5528.55 | 7649.63 |
5 | X3 | 30 | 4.0 | 1.0 | 12,942.93 | 984 | 964.5 | 990 |
6 | X1X3 | 70 | 4.0 | 1.0 | 2841.49 | 5047.30 | 3683.29 | 4144.34 |
7 | X2X3 | 30 | 6.0 | 1.0 | 15,081.284 | 989 | 978 | 949 |
8 | X1X2X3 | 70 | 6.0 | 1.0 | 5090.77 | 5660.94 | 3738.79 | 4541.39 |
9 | Mid-point | 50 | 5.0 | 0.8 | 8167.088 | 7808.8 | 1678.658 | 6681.036 |
13 | X1 − 2L | 10 | 5.0 | 0.8 | 591.83 | 491.08 | 521.66 | 738.19 |
14 | X1 + 2L | 90 | 5.0 | 0.8 | 5766.10 | 444.42 | 632.16 | 569.14 |
15 | X2 − 2L | 50 | 3.0 | 0.8 | 6269.09 | 4009.30 | 1688.17 | 1864.41 |
16 | X2 + 2L | 50 | 7.0 | 0.8 | 7678.7 | 3967.22 | 541.32 | 4069.66 |
17 | X3 − 2L | 50 | 5.0 | 0.4 | 10,603.02 | 8545.68 | 3623.83 | 6023.1 |
18 | X3 + 2L | 50 | 5.0 | 1.2 | 5649.47 | 4589.46 | 1650.81 | 3099.35 |